Recent events
Recent events tied to this brand in public sources.
Back to profile17 entries
2022
Sun Pharma subsidiary completes acquisition of Galderma subsidiaries
Sun Pharmaceutical Industries Limited subsidiary Taro Pharmaceuticals USA Inc completed the acquisition of Galderma subsidiaries, including entities incorporated in Delaware, Japan and Canada. The acquired subsidiaries sold products under the Proactiv, Restorative Elements and In Defense of Skin brands; the transaction price was $99.279 million.
2021
Sun Pharma Japan sells Kayaku Co. Ltd.
Sun Pharma Japan sold its entire shareholding in Kayaku Co. Ltd. to Shinshin Pharmaceutical Co., Ltd. for JPY 353,983,400; Kayaku ceased to be a Sun Pharmaceutical Industries subsidiary.
2021
Sun Pharma acquires Oxra trademark and manufacturing rights in India
Sun Pharma acquired the Indian rights to the Oxra, Oxramet and Oxraduo trademarks from AstraZeneca AB, and took a patent license from AstraZeneca AB to manufacture and commercialize dapagliflozin and its combination with metformin in India.
2021
Sun Pharma acquires Indian trademark rights for dapagliflozin products
Sun Pharma acquired the Indian rights to the Oxra, Oxramet and Oxraduo trademarks from AstraZeneca AB, with effect from 28 May 2021.
2021
Sun Pharma and AstraZeneca India discontinue distribution agreement
Sun Pharma and AstraZeneca India discontinued their 2016 distribution agreement, effective May 28, 2021.
2021
AstraZeneca India and Sun Pharma enter transition supply agreement
AstraZeneca India and Sun Pharma entered into a transition supply agreement effective May 28, 2021. AstraZeneca India will supply dapagliflozin and its combination with metformin to Sun Pharma until a mutually agreed point, after which those supplies will cease.
2021
AstraZeneca AB licenses dapagliflozin rights to Sun Pharma in India
AstraZeneca AB granted Sun Pharma a patent license to manufacture and commercialize dapagliflozin and its combination with metformin in India, effective 28 May 2021.
2021
Sun Pharma appoints two additional independent directors
Sun Pharma appointed Pawan Goenka and Rama Bijapurkar as additional independent directors, effective May 21, 2021.
2021
DigiHealth completes acquisition of 91.8% stake in Pharmarack Technologies
DigiHealth Technologies LLP completed the acquisition of a 91.8% stake in Pharmarack Technologies on April 5, 2021. Sun Pharmaceutical Industries announced the completion; DigiHealth is identified as an entity of an investee of the company's Indian wholly owned subsidiary.
2020
Sun Pharma recalls a lot of Riomet ER
Sun Pharmaceutical Industries Inc said it was voluntarily recalling one lot of Riomet ER oral suspension in the US because NDMA levels exceeded the allowable acceptable daily intake limit. The company said it had received no reports of adverse events related to the recall.
2020
Sun Pharma launches ILUMYA in Japan
Sun Pharma announced that its wholly owned Japanese subsidiary had launched ILUMYA Subcutaneous Injection 100 mg in Japan for adults with plaque psoriasis who have an inadequate response to conventional therapies.
2020
Sun Pharma recalls one lot of RIOMET ER
Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd., recalled one lot of RIOMET ER because of the potential presence of NDMA above the FDA-established acceptable daily intake limit. The company said it had received no reports of related adverse events to date.
2020
Sun Pharma recalls RIOMET ER bottles in the US over NDMA impurity
Sun Pharmaceutical Industries, through its US-based subsidiary, recalled 747 bottles of RIOMET ER in the US after NDMA impurity was detected in the finished drug product. The US regulator classified it as a Class II recall.
2020
DUSA reaches DOJ settlement over drug promotion allegations
DUSA Pharmaceuticals, a wholly owned subsidiary of Sun Pharmaceutical Industries, reached a civil settlement with the U.S. Department of Justice and agreed to pay $20.75 million to resolve allegations related to the promotion of LEVULAN KERASTICK and BLU-U. The settlement does not constitute an admission of liability or wrongdoing.
2020
Sun Pharma launches FluGuard in India
Sun Pharmaceutical Industries said it launched Favipiravir 200 mg in India under the FluGuard brand at Rs 35 per tablet for treatment of mild to moderate COVID-19 cases.
2020
Sun Pharma launches Flugard tablets for COVID-19 treatment
Sun Pharmaceutical Industries launched Flugard tablets containing 200 mg of favipiravir for COVID-19 patients in India. The article reports a price of 35 rupees per tablet and says market stock would be available that week.
2020
Sun Pharma launches Riomet ER in the US
Sun Pharmaceutical Industries said its wholly-owned subsidiary launched Riomet ER, a liquid formulation of extended-release metformin used to treat type 2 diabetes, in the US market.